Smart drugs fall short as cognitive function enhancers

NewsGuard 100/100 Score

Recently, there has been an increase in the use of stimulant prescription-only drugs by students and employees to increase their academic and other work productivity. Even though it has been perceived that these drugs enhance an individual’s cognitive functions, the available evidence is inconclusive. Typically, improvements in cognitive capacities have only been found in the clinical population instead of the general public. Interestingly, even in the clinical population, improvements in cognitive deficits were marginal. Therefore, there is a need to assess the effectiveness of these drugs in real-world conditions.

Study: Not so smart? “Smart” drugs increase the level but decrease the quality of cognitive effort. Image Credit: Victor Moussa / ShutterstockStudy: Not so smart? “Smart” drugs increase the level but decrease the quality of cognitive effort. Image Credit: Victor Moussa / Shutterstock

Background

Many everyday tasks can fall under the mathematical class of “hard” problems. Typically, these problems belong to the complexity class of nondeterministic polynomial (NP) hard. These tasks require systematic approaches (algorithms) for optimal outcomes. In the case of significant complex problems (e.g., the number of ways to fix a product or the number of stops to be made on a delivery trip), more computations are required, which rapidly outgrows cognitive capacities.

A recent Science Advances study investigated the effectiveness of three popular smart drugs, namely, modafinil (MOD), methylphenidate (MPH), and dextroamphetamine (DEX), against the difficulty of real-life daily tasks, i.e., the 0-1 knapsack optimization problem (“knapsack task”). A knapsack task is basically a combinatorial optimization task, the class of NP-time challenging problems.

MPH and DEX are catecholaminergic agonists which are associated with the enhancement of dopaminergic activity in cortical and subcortical areas. They also exhibit norepinephrine activity. However, MPH is an inhibitor of the dopamine and norepinephrine transporter.

About the Study

A total of 40 healthy individuals were recruited for the double-blinded, placebo (PLC)-controlled single-dose trial. This cohort included seventeen males and twenty-three females between 18 and 35 years of age. All participants underwent semistructured interviews and examinations before enrolment. Those volunteers with a history of heart disease, under psychotropic medication, neurological (e.g., epilepsy) or psychiatric illness, and pregnancy were excluded from the cohort.

Participants were required to attend four testing sessions, and each session had a minimum of seven days intervals. At each session, participants received one of either 200mg of MOD, 30 mg of MPH, 15 mg of DEX, or PLC. 

Here, participants were randomly assigned into four groups. Following a counterbalanced Latin square design, each group was provided with a different sequence of medications and PLC across sessions. During the knapsack task, each participant was presented with several items, which were associated with weight and value.

Participants were presented with eight unique instances of the knapsack task via a user interface. Some instances were less taxation to working memory and arithmetic, while others were purely numerical (more complex). Participants attempted each instance twice. A time limit of four minutes was allotted for each response. To analyze the compatibility of the study findings with prior experiments, participants were asked to complete four tasks from the CANTAB cognitive battery.

Study Findings

Even though drug treatment did not result in a significant drop in the chance of getting a solution to the knapsack problem instances, it positively caused a significant overall reduction in attained value. The time spent or the effort levels significantly improved on average in the participants under smart drugs. However, heterogeneity in the quality of effort linked to each drug was observed compared to PLC. Effort quality was described as the improvements in knapsack value per move.

Interestingly, if an individual under PLC exhibited a significant increase in knapsack value per move, the same person tended to be below average under smart drugs. Similarly, for an individual who performed below average under PLC, the quality of effort was above average under smart drugs. This reversal in effort quality could be because participants were found to be more erratic in their choices under smart drugs.

All tasks were computationally demanding, and responses required systemic thought. The tasks were designed in such a manner that random exploration was not effective. Good effort allocation is the key need for the knapsack task. Smart drugs enhance subjective reward, and in parallel, they reduce perceived effort. These drugs have a negative impact on efficacy.

All three smart drugs reduced the performance of participants in some of the CANTAB tasks included in this study. This study was unable to determine the individual drug effects in the knapsack task based on the CANTAB task values. 

Conclusions

The current study provided insights into how smart drugs affect the day-to-day functioning of patients suffering from attention deficit hyperactivity disorder (ADHD). It was found that smart drugs only improved motivation to do work but not the quality of effort.

Journal reference:
 
Dr. Priyom Bose

Written by

Dr. Priyom Bose

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bose, Priyom. (2023, July 01). Smart drugs fall short as cognitive function enhancers. News-Medical. Retrieved on May 21, 2024 from https://www.news-medical.net/news/20230618/Smart-drugs-fall-short-as-cognitive-function-enhancers.aspx.

  • MLA

    Bose, Priyom. "Smart drugs fall short as cognitive function enhancers". News-Medical. 21 May 2024. <https://www.news-medical.net/news/20230618/Smart-drugs-fall-short-as-cognitive-function-enhancers.aspx>.

  • Chicago

    Bose, Priyom. "Smart drugs fall short as cognitive function enhancers". News-Medical. https://www.news-medical.net/news/20230618/Smart-drugs-fall-short-as-cognitive-function-enhancers.aspx. (accessed May 21, 2024).

  • Harvard

    Bose, Priyom. 2023. Smart drugs fall short as cognitive function enhancers. News-Medical, viewed 21 May 2024, https://www.news-medical.net/news/20230618/Smart-drugs-fall-short-as-cognitive-function-enhancers.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Freshness matters: Study finds newer honey packs a stronger antibacterial punch